English  丨  中文

One of our core strengths is our commitment to consolidating and expanding our intellectual property (IP) portfolio in the areas of multi-targeted siRNA therapeutics, We currently hold a strong portfolio of intellectual property with following features:

1. Composition Matters: 25 mer blunt-ends siRNA API(s) and polypeptide excipient(s)

2. Method of Use: nanoparticle packaged siRNA duplexes for local or systemic administration

3. Utilities: unmet clinical needs with big market potential, such as hypertrophic scar prevention and treatment, influenza prophylaxis and therapeutics, cancer treatment.

4. In-house developed: 10 PCTs, 2 US patent applications. 5 European and China national phase applications. Three issued US patents protecting STP705, STP702 and STP503.

5. Licensing: 2 issued patents licensed from Prof. James Mixson and University of Hong Kong, China.